Cardiac Transplantation in Patients With Hypertrophic Cardiomyopathy

被引:47
|
作者
Kato, Tomoko S. [1 ]
Takayama, Hiroo [2 ]
Yoshizawa, Saeko [3 ]
Marboe, Charles [3 ]
Schulze, P. Christian [1 ]
Farr, Maryjane [1 ]
Naka, Yoshifumi [2 ]
Mancini, Donna [1 ]
Maurer, Mathew S. [1 ]
机构
[1] Columbia Univ, Dept Med, Div Cardiol, Med Ctr, New York, NY 10027 USA
[2] Columbia Univ, Dept Surg, Div Cardiothorac Surg, Med Ctr, New York, NY USA
[3] Columbia Univ, Dept Pathol, Med Ctr, New York, NY USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2012年 / 110卷 / 04期
关键词
MUSCLE CELL DISORGANIZATION; LEFT-VENTRICULAR HYPERTROPHY; HEART-TRANSPLANTATION; CLINICAL-SIGNIFICANCE; ATHLETES HEART; SURVIVAL; PREVALENCE; INFECTION; DIAGNOSIS; FEATURES;
D O I
10.1016/j.amjcard.2012.04.030
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiac transplantation is a treatment option for patients with hypertrophic cardiomyopathy (HC) who developed refractory heart failure and/or intractable arrhythmia. However, the pretransplant characteristics and post-transplant prognosis for patients with nondilated idiopathic HC has not yet fully elucidated. Therefore, we retrospectively reviewed 813 consecutive transplant recipients undergoing cardiac transplantation at Columbia University Medical Center from 1999 to 2010 and compared the clinical course of 41 patients with idiopathic HC with that of 373 patients with ischemic heart disease and 398 patients with other heart disease. The patients with HC were younger than those with ischemic heart disease (47.8 +/- 14.0 vs 57.1 +/- 9.4 years; p <0.0001). The proportion of patients undergoing ventricular assist devise surgery for bridge-to-transplant was lower in patients with HC than in those with ischemic heart disease or other heart disease (14.6% vs 31.1% vs 35.7%, all p <0.01). The post-transplant survival of those with HC was better than that for those with ischemic heart disease (90.1% vs 85.8% and 83.9% vs 67.1% at 1 and 5 years, respectively; p = 0.0359), although it was not significantly different from those with other heart disease. Proportional hazards analysis revealed that the subjects with HC had reduced post-transplant mortality (hazard ratio 0.4760, 95% confidential interval 0.1889 to 0.9762; p = 0.042) on univariate, but not multivariate, analysis. Most patients with HC had nondilated left ventricles (left ventricular end-diastolic dimension <= 55 mm; n = 27), and post-transplant survival did not differ from that for those with dilated left ventricles (left ventricular end-diastolic dimension >55 mm; n = 14). In conclusion, the post-transplant survival of those with HC did not differ from those of the subjects who underwent transplant for other non-HC indications. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;110:568-574)
引用
收藏
页码:568 / 574
页数:7
相关论文
共 50 条
  • [41] Cardiac transplantation outcomes in patients with amyloid cardiomyopathy
    Ohiomoba, Ramael O.
    Youmans, Quentin R.
    Ezema, Ashley
    Akanyirige, P.
    Anderson, Allen S.
    Bryant, A.
    Jackson, Kamari
    Mandieka, Edwin
    Pham, Duc T.
    Rich, Jonathan D.
    Yancy, Clyde W.
    Okwuosa, Ike S.
    AMERICAN HEART JOURNAL, 2021, 236 : 13 - 21
  • [42] Cardiac transplantation in patients with iron overload cardiomyopathy
    Caines, AE
    Kpodonu, J
    Massad, MG
    Chaer, R
    Evans, A
    Lee, JC
    Geha, AS
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (04): : 486 - 488
  • [43] SUDDEN CARDIAC DEATH IN HYPERTROPHIC CARDIOMYOPATHY
    MARON, BJ
    FANANAPAZIR, L
    CIRCULATION, 1992, 85 (01) : 57 - 63
  • [44] Sudden Cardiac Death in Hypertrophic Cardiomyopathy
    Adamczak, Daria M.
    Oko-Sarnowska, Zofia
    CARDIOLOGY IN REVIEW, 2018, 26 (03) : 145 - 151
  • [45] CARDIAC HAMARTOMA MASQUERADING AS HYPERTROPHIC CARDIOMYOPATHY
    Shekiladze, Nikoloz
    Mohandas, Appesh
    Bakhtadze, Beka
    Koshkelashvili, Nikoloz
    Meng-Jun, Xiong
    Gadiyaram, Varuna
    El-Chami, Mikhael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 2257 - 2257
  • [46] CARDIAC TAMPONADE FACILITATED BY HYPERTROPHIC CARDIOMYOPATHY
    James, Chris
    Yuvaraj, Yaswanraj
    Girard, Michael J.
    Patton, Marquand
    CHEST, 2023, 164 (04) : 475A - 475A
  • [47] CARDIAC NOREPINEPHRINE KINETICS IN HYPERTROPHIC CARDIOMYOPATHY
    BRUSH, JE
    EISENHOFER, G
    GARTY, M
    STULL, R
    MARON, BJ
    CANNON, RO
    PANZA, JA
    EPSTEIN, SE
    GOLDSTEIN, DS
    CIRCULATION, 1989, 79 (04) : 836 - 844
  • [48] Cardiac sarcoidosis presenting as hypertrophic cardiomyopathy
    Haley, Ryan
    Crimm, Hampton
    Hulten, Edward
    Huffer, Linda
    Flanagan, Michael Casey
    EUROPEAN HEART JOURNAL, 2017, 38 (30) : 2377 - 2377
  • [49] CARDIAC AMYLOIDOSIS SIMULATING HYPERTROPHIC CARDIOMYOPATHY
    SEDLIS, SP
    SAFFITZ, JE
    SCHWOB, VS
    JAFFE, AS
    AMERICAN JOURNAL OF CARDIOLOGY, 1984, 53 (07): : 969 - 970
  • [50] Cardiac amyloidosis mimicking hypertrophic cardiomyopathy
    Cortes, Marcia M.
    Battioni, Luciano
    Sciancalepore, Agustina
    Costabel, Juan P.
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2015, 44 (04): : 229 - 231